A business leader in biotech for 25 years, Deidre Roniger has a successful track record of bringing clarity to complex situations, understanding risk, and driving quality decisions across company stages from PC to commercialization, and therapeutic areas. She is known for her strong strategic agility, adaptability, and problem solving in various settings of company maturity from large Biopharma to startups. Experience includes P&L leadership, people management, culture change, developing long range plans and financing strategies, fundraising, and pre-launch planning.
Previously, Deidre served as SVP Corporate Development at Ambys Medicine a cell therapy start-up and was a Managing Partner at DNA Ink, a boutique life sciences consulting firm offering corporate strategy and transaction services for C-suite clients in biotech, medtech and pharma. She developed organic and inorganic growth strategies across the client base and participated in licensing efforts on multiple deals. Her previous experience includes nearly a decade at Genentech, where she held operational and leadership roles of increasing responsibility across the commercial organization. Throughout her career at Genentech, Deidre had P&L responsibility for a $250 million franchise for which she led the turn-around effort, managed a cost center of $75 million and was accountable for the accurate forecasting and analytical support of Genentech’s full portfolio of products and in-licensing opportunities. She led the Market Analysis & Strategy group at Genentech, overseeing over 110 FTEs, and was accountable for all analytical support.
Deidre earned an MBA from Wake Forest University and holds a BS in Biochemistry from the UC San Diego. In 2007, she was named Healthcare Business Women’s Association Rising Star. Selected for and completed Executive Women in Bio Boardroom Ready Program 2020.